NASDAQ : BBIO
BridgeBio Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 74.95 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.65B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.60B |
| Enterprise Value | 16.44B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 194.80M |
| Shares Outstanding | 194.80M |
| Shares Change (YoY) | +2.39% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 3.95% |
| Owned by Institutions (%) | 87.81% |
| Float | 166.51M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.44 |
| Forward PS | 9.95 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 17.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.09 |
| Quick Ratio | 1.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.66 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -13.97% |
| Return on Invested Capital (ROIC) | -17.67% |
| Return on Capital Employed (ROCE) | -29.81% |
| Weighted Average Cost of Capital (WACC) | 8.73% |
| Revenue Per Employee | $942,712 |
| Profits Per Employee | -$590,354 |
| Employee Count | 1,003 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.27 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.11M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +12.50% |
| 50-Day Moving Average | 70.27 |
| 200-Day Moving Average | 72.74 |
| Relative Strength Index (RSI) | 70.17 |
| Average Volume (20 Days) | 2,805,148 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20.00M |
| Short Previous Month | 19.67M |
| Short % of Shares Out | 10.27% |
| Short % of Float | 12.01% |
| Short Ratio (days to cover) | 6.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 945.54M |
| Gross Profit | 892.00M |
| Operating Income | -353.11M |
| Pretax Income | -576.47M |
| Net Income | -592.13M |
| EBITDA | -348.36M |
| EBIT | -353.11M |
| Loss Per Share | -$3.04 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.54B |
| Total Debt | 3.38B |
| Net Cash | -1.84B |
| Net Cash Per Share | -$9.44 |
| Equity (Book Value) | -1.65B |
| Book Value Per Share | -13.29 |
| Working Capital | 1.07B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -368.97M |
| Capital Expenditures | -835,000 |
| Depreciation & Amortization | 4.74M |
| Net Borrowing | 576.89M |
| Free Cash Flow | -369.81M |
| FCF Per Share | -$1.90 |
Margins
| Measure | Value |
|---|
| Gross Margin | 94.34% |
| Operating Margin | -37.34% |
| Pretax Margin | -60.97% |
| Profit Margin | -59.84% |
| EBITDA Margin | -36.84% |
| EBIT Margin | -37.34% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.39% |
| Shareholder Yield | -2.39% |
| Earnings Yield | -4.05% |
| FCF Yield | -2.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $106.75 |
| Price Target Difference | 42.43% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 72.22% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.04 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |